DOXAZOSIN MESYLATE Drug Patent Profile
✉ Email this page to a colleague
When do Doxazosin Mesylate patents expire, and when can generic versions of Doxazosin Mesylate launch?
Doxazosin Mesylate is a drug marketed by Accord Hlthcare, Actavis Elizabeth, Ani Pharms, Apotex, Aurobindo Pharma Usa, Chartwell Rx, Genpharm, Heritage Pharma, Ivax Sub Teva Pharms, Nesher Pharms, Pliva, Rising, Somerset Theraps Llc, Strides Pharma Intl, Teva, Unichem, Watson Labs Inc, and Zydus Pharms. and is included in nineteen NDAs.
The generic ingredient in DOXAZOSIN MESYLATE is doxazosin mesylate. There is one drug master file entry for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Doxazosin Mesylate
A generic version of DOXAZOSIN MESYLATE was approved as doxazosin mesylate by APOTEX on October 18th, 2000.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DOXAZOSIN MESYLATE?
- What are the global sales for DOXAZOSIN MESYLATE?
- What is Average Wholesale Price for DOXAZOSIN MESYLATE?
Summary for DOXAZOSIN MESYLATE
| US Patents: | 0 |
| Applicants: | 18 |
| NDAs: | 19 |
| Finished Product Suppliers / Packagers: | 29 |
| Raw Ingredient (Bulk) Api Vendors: | 84 |
| Clinical Trials: | 2 |
| Patent Applications: | 2,112 |
| Drug Prices: | Drug price information for DOXAZOSIN MESYLATE |
| What excipients (inactive ingredients) are in DOXAZOSIN MESYLATE? | DOXAZOSIN MESYLATE excipients list |
| DailyMed Link: | DOXAZOSIN MESYLATE at DailyMed |
Recent Clinical Trials for DOXAZOSIN MESYLATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |
| Pfizer | |
| National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
Pharmacology for DOXAZOSIN MESYLATE
| Drug Class | alpha-Adrenergic Blocker |
| Mechanism of Action | Adrenergic alpha-Antagonists |
